Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Wall Street's top stories for Friday » 16:39
04/09/21
04/09
16:39
04/09/21
16:39
BA

Boeing

$252.36 /

-2.5 (-0.98%)

, AMZN

Amazon.com

$3,371.40 /

+73.69 (+2.23%)

, CCK

Crown Holdings

$104.85 /

+2.86 (+2.80%)

, AZN

AstraZeneca

$49.95 /

+0.465 (+0.94%)

, JNJ

Johnson & Johnson

$161.20 /

-1.74 (-1.07%)

, PFE

Pfizer

$36.60 /

+0.64 (+1.78%)

, BNTX

BioNTech

$122.15 /

+7.68 (+6.71%)

, FUBO

FuboTV

$23.30 /

+2.605 (+12.59%)

, LEVI

Levi Strauss

$25.69 /

+0.675 (+2.70%)

, PRVB

Provention Bio

$8.00 /

-1.72 (-17.70%)

, JKS

JinkoSolar

$38.66 /

-0.2 (-0.51%)

The major averages closed…

ShowHide Related Items >><<
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
PFE Pfizer
$36.60 /

+0.64 (+1.78%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

04/05/21 Evercore ISI
FuboTV assumed with an Outperform at Evercore ISI
03/29/21 Needham
Needham lays out 'bull case' on 'inexpensive' FuboTV shares
03/09/21 Oppenheimer
FuboTV price target lowered to $35 from $45 at Oppenheimer
03/08/21 Alliance Global Partners
Chicken Soup for the Soul initiated with a Buy at Alliance Global Partners
LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

04/09/21 UBS
Levi Strauss price target raised to $34 from $29 at UBS
04/09/21 Citi
Levi Strauss price target raised to $29 from $25 at Citi
01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

04/09/21 SVB Leerink
Provention Bio price target lowered to $16 from $26 at SVB Leerink
04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

  • 14
    Jan
  • 30
    Dec
  • 08
    Oct
  • 23
    Jul
  • 18
    Jun
PFE Pfizer
$36.60 /

+0.64 (+1.78%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

PRVB Provention Bio
$8.00 /

-1.72 (-17.70%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

CCK Crown Holdings
$104.85 /

+2.86 (+2.80%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

PFE Pfizer
$36.60 /

+0.64 (+1.78%)

LEVI Levi Strauss
$25.69 /

+0.675 (+2.70%)

JNJ Johnson & Johnson
$161.20 /

-1.74 (-1.07%)

JKS JinkoSolar
$38.66 /

-0.2 (-0.51%)

FUBO FuboTV
$23.30 /

+2.605 (+12.59%)

BNTX BioNTech
$122.15 /

+7.68 (+6.71%)

BA Boeing
$252.36 /

-2.5 (-0.98%)

AZN AstraZeneca
$49.95 /

+0.465 (+0.94%)

AMZN Amazon.com
$3,371.40 /

+73.69 (+2.23%)

Periodicals
J&J in talks for trial in India of COVID-19 vaccine, Business Standard says » 15:00
04/09/21
04/09
15:00
04/09/21
15:00
JNJ

Johnson & Johnson

$160.37 /

-2.57 (-1.58%)

A Johnson & Johnson…

A Johnson & Johnson India spokesperson told the Business Standard: "At J&J, we remain fully focused on bringing a safe and effective Covid-19 vaccine to people around the world, if authorised for use by local health authorities. We are in discussions with the Government of India with the objective of starting clinical study of our Janssen Covid-19 vaccine candidate in India, subject to local regulatory nod." However, at this point, approval to start clinical trials has not been granted to the company, a source close to the development confirmed to Business Standard's Sohini Das. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

JNJ Johnson & Johnson
$160.37 /

-2.57 (-1.58%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:54
04/09/21
04/09
12:54
04/09/21
12:54
BA

Boeing

$251.71 /

-3.15 (-1.24%)

, AMZN

Amazon.com

$3,352.25 /

+54.54 (+1.65%)

, CCK

Crown Holdings

$104.06 /

+2.07 (+2.03%)

, AZN

AstraZeneca

$49.80 /

+0.315 (+0.64%)

, JNJ

Johnson & Johnson

$159.95 /

-2.99 (-1.84%)

, AFMD

Affimed

$9.73 /

+1.86 (+23.63%)

, LEVI

Levi Strauss

$25.48 /

+0.465 (+1.86%)

, PRVB

Provention Bio

$8.20 /

-1.52 (-15.64%)

, JKS

JinkoSolar

$38.04 /

-0.82 (-2.11%)

The major averages are…

ShowHide Related Items >><<
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

04/09/21 Baird
Baird says add to Boeing on any weakness due to 'tiny fix' needed for MAX jets
03/29/21 Goldman Sachs
Boeing resuming 787 deliveries removes overhang, says Goldman Sachs
03/19/21 Susquehanna
Boeing price target raised to $300 from $250 at Susquehanna
03/15/21 Morgan Stanley
Aerospace sector upgraded to Attractive from Cautious at Morgan Stanley
AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

04/05/21 Evercore ISI
Amazon.com assumed with an Outperform at Evercore ISI
04/01/21 Wedbush
Microsoft gets another major win within the beltway, says Wedbush
04/01/21 Credit Suisse
Ubiquiti price target lowered to $126 from $157 at Credit Suisse
03/31/21 Wolfe Research
Amazon.com assumed with an Outperform at Wolfe Research
CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

04/09/21 Goldman Sachs
Crown Holdings initiated with a Neutral at Goldman Sachs
02/11/21 Citi
Crown Holdings price target raised to $125 from $117 at Citi
02/11/21 Barclays
Crown Holdings price target raised to $122 from $103 at Barclays
01/26/21 BMO Capital
Sonoco Products downgraded to Market Perform from Outperform at BMO Capital
AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
AFMD Affimed
$9.73 /

+1.86 (+23.63%)

03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/30/21 Credit Suisse
Affimed N.V. initiated with an Outperform at Credit Suisse
03/24/21 Wells Fargo
Affimed N.V. price target raised to $15 from $10 at Wells Fargo
03/10/21 BMO Capital
BMO Capital ups Affimed N.V. target to $12 following AFM13 interim analysis
LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

04/09/21 UBS
Levi Strauss price target raised to $34 from $29 at UBS
04/09/21 Citi
Levi Strauss price target raised to $29 from $25 at Citi
01/27/21 Citi
Levi Strauss price target raised to $25 from $19 at Citi
01/07/21 JPMorgan
Levi Strauss price target raised to $21 from $18 at JPMorgan
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

04/09/21 SVB Leerink
Provention Bio price target lowered to $16 from $26 at SVB Leerink
04/09/21 RBC Capital
Provention Bio cut to Sector Perform at RBC Capital after teplizumab FDA notice
04/09/21 Cantor Fitzgerald
Provention Bio price target lowered to $25 from $27 at Cantor Fitzgerald
04/09/21 RBC Capital
Provention Bio downgraded to Sector Perform from Outperform at RBC Capital
JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

02/08/21 Roth Capital
Bill could be 'meaningful positive' for solar stocks, says Roth Capital
01/04/21 Goldman Sachs
JinkoSolar price target raised to $39 from $34 at Goldman Sachs
12/30/20 GLJ Research
GLJ Research keeps Sell on JinkoSolar after chairman, CEO dump shares
12/21/20 Roth Capital
ITC/PTC extensions likely included in COVID relief package, says Roth Capital
PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

  • 14
    Jan
  • 13
    Jan
  • 18
    Jun
JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

PRVB Provention Bio
$8.20 /

-1.52 (-15.64%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

CCK Crown Holdings
$104.06 /

+2.07 (+2.03%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

AFMD Affimed
$9.73 /

+1.86 (+23.63%)

LEVI Levi Strauss
$25.48 /

+0.465 (+1.86%)

JNJ Johnson & Johnson
$159.95 /

-2.99 (-1.84%)

JKS JinkoSolar
$38.04 /

-0.82 (-2.11%)

BA Boeing
$251.71 /

-3.15 (-1.24%)

AZN AstraZeneca
$49.80 /

+0.315 (+0.64%)

AMZN Amazon.com
$3,352.25 /

+54.54 (+1.65%)

Periodicals
EU evaluates J&J vaccine for blood clots, widens AstraZeneca probe, Reuters says » 10:07
04/09/21
04/09
10:07
04/09/21
10:07
AZN

AstraZeneca

$49.96 /

+0.475 (+0.96%)

, JNJ

Johnson & Johnson

$161.97 /

-0.97 (-0.60%)

The European Medicines…

The European Medicines Agency is evaluating reports of a bleeding condition in people after receiving AstraZeneca's (AZN) COVID-19 vaccine as well as reviewing Johnson & Johnson's (JNJ) shot over reports of rare blood clots, Reuters' reports, citing the agency. The EMA said four serious cases of rare blood clots with low platelets, one of which was fatal, have been reported after inoculation with J&J's vaccine and five cases of capillary leak syndrome linked to AstraZeneca's vaccine were reported. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

JNJ Johnson & Johnson
$161.97 /

-0.97 (-0.60%)

AZN AstraZeneca
$49.96 /

+0.475 (+0.96%)

Thursday
Periodicals
North Carolina halts Johnson&Johnson COVID shots on adverse reactions, AP says » 20:18
04/08/21
04/08
20:18
04/08/21
20:18
JNJ

Johnson & Johnson

$162.94 /

-0.65 (-0.40%)

COVID vaccine sites in…

COVID vaccine sites in North Carolina have stopped administering the Johnson & Johnson-made vaccine after at least 26 people experienced adverse reactions that included fainting, AP News' Bryan Anderson reports. State and federal health officials are reviewing the matter, Anderson writes, adding that Colorado has also paused its J&J vaccine earlier this week when 11 people experienced adverse reactions. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

JNJ Johnson & Johnson
$162.94 /

-0.65 (-0.40%)

Periodicals
Mass vaccination site closed temporarily following adverse reactions, WSJ says » 13:59
04/08/21
04/08
13:59
04/08/21
13:59
JNJ

Johnson & Johnson

$163.51 /

-0.08 (-0.05%)

A Colorado…

A Colorado mass-vaccination site was closed Wednesday after 11 people experienced adverse effects after being given a shot of the Johnson & Johnson Covid-19 vaccine, The Wall Street Journal's Talal Ansari reports. "Medical staff on site determined two individuals required additional observation and out of an abundance of caution, they were transported to a nearby hospital," Centura Health, which runs the site along with the state of Colorado, said in a statement. It is unclear whether the adverse reactions were related to the vaccine. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

JNJ Johnson & Johnson
$163.51 /

-0.08 (-0.05%)

Conference/Events
Cantor biotech/biopharma analysts hold analyst/industry conference call » 12:25
04/08/21
04/08
12:25
04/08/21
12:25
REGN

Regeneron

$478.41 /

-2.97 (-0.62%)

, LLY

Eli Lilly

$183.41 /

+1.12 (+0.61%)

, BMY

Bristol-Myers

$62.20 /

+0.15 (+0.24%)

, PFE

Pfizer

$35.96 /

+0.05 (+0.14%)

, JNJ

Johnson & Johnson

$163.36 /

-0.23 (-0.14%)

, ARQT

Arcutis Biotherapeutics

$27.67 /

-0.32 (-1.14%)

, INCY

Incyte

$81.25 /

-0.205 (-0.25%)

, ACRS

Aclaris Therapeutics

$29.96 /

+0.38 (+1.28%)

, PHGE

BiomX

$6.29 /

-0.07 (-1.10%)

, VYNE

VYNE Therapeutics

$6.47 /

+0.03 (+0.47%)

Biopharma Analysts Chen…

Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PHGE BiomX
$6.29 /

-0.07 (-1.10%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
PFE Pfizer
$35.96 /

+0.05 (+0.14%)

04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
INCY Incyte
$81.25 /

-0.205 (-0.25%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
PHGE BiomX
$6.29 /

-0.07 (-1.10%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

  • 03
    Feb
  • 20
    Jan
  • 02
    Oct
  • 27
    May
REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

Periodicals
Official warned that Emergent plant had to be 'monitored closely,' NYT reports » 05:58
04/08/21
04/08
05:58
04/08/21
05:58
EBS

Emergent BioSolutions

$78.77 /

-0.42 (-0.53%)

, JNJ

Johnson & Johnson

$163.63 /

+0.29 (+0.18%)

, AZN

AstraZeneca

$48.44 /

-0.78 (-1.58%)

A top federal pandemic…

A top federal pandemic official warned last June that Emergent BioSolutions (EBS), which recently threw out millions of doses of Covid-19 vaccines because of contamination, lacked enough trained staff and had a record of problems with quality control, The New York Times' Sheryl Gay Stolberg, Sharon LaFraniere and Chris Hamby report. The report, which was written by Carlo de Notaristefani, a manufacturing expert who has overseen production of Covid-19 vaccines for the federal government since last May, cited "key risks" in relying on Emergent to handle the production of vaccines developed by both Johnson & Johnson (JNJ) and AstraZeneca (AZN) at Emergent's Baltimore plant. Addressing the problems "will require significant effort," and the company "will have to be monitored closely," the official said in the report. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

EBS Emergent BioSolutions
$78.77 /

-0.42 (-0.53%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

EBS Emergent BioSolutions
$78.77 /

-0.42 (-0.53%)

04/07/21
Fly Intel: Top five analyst initiations
04/07/21 Benchmark
Benchmark starts Emergent at Buy, thinks shares can resume upward momentum
04/07/21 Benchmark
Emergent BioSolutions initiated with a Buy at Benchmark
02/24/21 Chardan
Chardan reverses last week's downgrade, upgrades Emergent to Buy
JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

04/07/21 Citi
FibroGen update creates only 'bad optic' for AstraZeneca, says Citi
03/26/21 Piper Sandler
AstraZeneca plan 'opens the door' for Altimmune interest, says Piper Sandler
03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

EBS Emergent BioSolutions
$78.77 /

-0.42 (-0.53%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

EBS Emergent BioSolutions
$78.77 /

-0.42 (-0.53%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

EBS Emergent BioSolutions
$78.77 /

-0.42 (-0.53%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

AZN AstraZeneca
$48.44 /

-0.78 (-1.58%)

Conference/Events
Cantor biotech/biopharma analysts hold analyst/industry conference call » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
REGN

Regeneron

$481.38 /

+2.48 (+0.52%)

, LLY

Eli Lilly

$182.31 /

-0.31 (-0.17%)

, BMY

Bristol-Myers

$62.05 /

+0.07 (+0.11%)

, PFE

Pfizer

$35.90 /

-0.14 (-0.39%)

, JNJ

Johnson & Johnson

$163.63 /

+0.29 (+0.18%)

, ARQT

Arcutis Biotherapeutics

$27.99 /

+0.19 (+0.68%)

, INCY

Incyte

$81.33 /

-1.8 (-2.17%)

, ACRS

Aclaris Therapeutics

$29.59 /

+0.74 (+2.56%)

, PHGE

BiomX

$6.31 /

-0.1 (-1.56%)

, VYNE

VYNE Therapeutics

$6.44 /

-0.29 (-4.31%)

Biopharma Analysts Chen…

Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PHGE BiomX
$6.31 /

-0.1 (-1.56%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
PFE Pfizer
$35.90 /

-0.14 (-0.39%)

04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
INCY Incyte
$81.33 /

-1.8 (-2.17%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
PHGE BiomX
$6.31 /

-0.1 (-1.56%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

  • 03
    Feb
  • 20
    Jan
  • 02
    Oct
  • 27
    May
REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

Tuesday
Periodicals
Biden to say all U.S. adults should be vaccine-eligible by April 19, WSJ says » 13:00
04/06/21
04/06
13:00
04/06/21
13:00
SPX

S&P 500

$0.00 /

+ (+0.00%)

, SPY

SPDR S&P 500 ETF Trust

$406.83 /

+0.53 (+0.13%)

, PFE

Pfizer

$36.26 /

-0.02 (-0.06%)

, BNTX

BioNTech

$117.33 /

+2.05 (+1.78%)

, MRNA

Moderna

$137.40 /

+7.63 (+5.88%)

, JNJ

Johnson & Johnson

$164.00 /

+0.61 (+0.37%)

U.S. President Joe Biden…

U.S. President Joe Biden plans to say that all U.S. adults should be eligible for coronavirus vaccines by April 19, expediting the timeline he established last month, the Wall Street Journal's Ken Thomas reports, citing an administration official. All states except for Hawaii have said they will meet that timeline, Thomas says. Ahead of the upcoming announcement, the White House asked states if they could hit the new goal for expanding eligibility, Thomas notes, citing a person familiar with the conversations. The Fly notes that the U.S. has so far approved COVID-19 vaccines from Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

ShowHide Related Items >><<
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

MRNA Moderna
$137.40 /

+7.63 (+5.88%)

JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

BNTX BioNTech
$117.33 /

+2.05 (+1.78%)

SPX S&P 500
$0.00 /

+ (+0.00%)

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
03/12/21
On The Fly: Weekly technical notes for S&P 500
01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
SPY SPDR S&P 500 ETF Trust
$406.83 /

+0.53 (+0.13%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
BNTX BioNTech
$117.33 /

+2.05 (+1.78%)

02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
MRNA Moderna
$137.40 /

+7.63 (+5.88%)

03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
03/01/21 Chardan
Moderna price target raised to $182 from $107 at Chardan
02/26/21 Barclays
Moderna price target raised to $178 from $169 at Barclays
02/26/21 Brookline
Moderna price target raised to $205 from $180 at Brookline
JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

MRNA Moderna
$137.40 /

+7.63 (+5.88%)

JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

  • 23
    Jul
  • 19
    May
SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

MRNA Moderna
$137.40 /

+7.63 (+5.88%)

JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

MRNA Moderna
$137.40 /

+7.63 (+5.88%)

JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

SPY SPDR S&P 500 ETF Trust
$406.83 /

+0.53 (+0.13%)

SPX S&P 500
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.26 /

-0.02 (-0.06%)

MRNA Moderna
$137.40 /

+7.63 (+5.88%)

JNJ Johnson & Johnson
$164.00 /

+0.61 (+0.37%)

BNTX BioNTech
$117.33 /

+2.05 (+1.78%)

SPY SPDR S&P 500 ETF Trust
$406.83 /

+0.53 (+0.13%)

SPX S&P 500
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.